Inhaled amikacin to prevent pneumonia in cirrhosis patients on ventilators
Part of Brain & nervous system, Digestive system, Hormones & metabolism, Infections, Lungs & breathing clinical trials.
This trial tests whether inhaling an antibiotic called amikacin can prevent ventilator-associated pneumonia in patients with severe liver disease (cirrhosis) who are on a breathing machine. If you or your loved one is in the ICU with liver issues and needs a ventilator, this study may help reduce the risk of a serious lung infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are in the liver ICU with severe confusion (hepatic encephalopathy) and need a breathing tube for at least 48 hours.
- You do not have pneumonia when the study starts.
- You are 18 years or older.
- You do not have chronic kidney disease needing regular dialysis.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an inhaled antibiotic called colistin can prevent pneumonia in patients with brain injuries who are on ventilators. If effective, it could reduce lung infections and improve recovery.
This trial tests if inhaling a medication called colistin can prevent ventilator-associated pneumonia (a lung infection) in patients who are on a breathing machine. It aims to reduce the risk for those at high risk of getting an infection from drug-resistant bacteria.
This study tests whether adding an inhaled antibiotic (polymyxin) to standard IV antibiotics helps treat a severe lung infection that is resistant to many drugs. It is for people who had a stroke and developed this infection while on a breathing machine. The inhaled drug is delivered directly to the lungs, which might improve treatment and reduce side effects.
This trial tests whether giving preventive antibiotics to adults on breathing machines lowers the risk of developing pneumonia during ventilation. It is a double-blind study, meaning neither you nor your doctor will know if you receive the antibiotic or a placebo.
This trial tests whether an inhaled antibiotic (amikacin) can help clear a lung infection called ventilator-associated tracheobronchitis in patients who are on a breathing machine. It may reduce infection and improve recovery.
This trial tests whether adding an inhaled antibiotic (amikacin) to standard IV antibiotics can better treat a serious lung infection (pneumonia caused by Gram-negative bacteria) in patients on a heart-lung machine (ECMO) and a breathing tube. If you or your loved one is on ECMO and has this type of pneumonia, this study may offer a new treatment approach.
Hear when a new Hepatic Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.